Q-omics provides the consensus-scored SETBP1-DT profile across patient tissues and cancer cell-line models. SETBP1-DT expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SETBP1-DT is differentially expressed in 17, with the highest sampling consensus in KIRP. Additionally, SETBP1-DT RNA expression shows 18,420 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRP, and THYM as cancer lineages where SETBP1-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SETBP1-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SETBP1-DT survival associations across molecular data types. SETBP1-DT RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SETBP1-DT RNA expression–survival associations across cancer types. High SETBP1-DT expression shows unfavorable associations in UVM and BLCA, but favorable associations in PAAD, KIRC, UCS and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SETBP1-DT RNA expression.
This table summarizes SETBP1-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SETBP1-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SETBP1-DT shows lower tumor expression in KIRP, THCA, COAD, KIRC, KICH and BLCA. The KIRP box plot shows higher SETBP1-DT RNA expression in normal versus tumor tissue (log2 FC = −1.072, t-test p < 0.001).
This table shows molecular features associated with SETBP1-DT in patient tissues and cancer cell lines. In patient samples, SETBP1-DT shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
